---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266731"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-06-11T12:09:27+00:00"
generated_at: "2026-06-11T12:10:08.178703+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven reports 61% overall MMR at 80 mg QD in Phase 1b; FDA aligns on Phase 3 design for ELVN-001

## Summary
- 161 patients enrolled; median treatment duration 35 weeks; 76% remain on study as of March 10, 2026 cutoff.
- 61% overall MMR and 48% achieved MMR by 24 weeks in the 80 mg QD Phase 1b cohort (n=28 evaluable).
- 70% of patients had 3+ prior TKIs; 62% had prior asciminib; response rates comparable regardless of prior asciminib exposure.
- Only 6% discontinued due to adverse events; Grade ≥3 TEAEs at 80 mg QD were 24% with thrombocytopenia the most common at 6%.
- FDA endorsed 80 mg QD as Phase 3 dose and 2L+ patient population; ENABLE-2 pivotal trial expected to initiate H2 2026.

## SEC filing metadata
- accession: 0001193125-26-266731
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-06-11T12:09:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526266731/0001193125-26-266731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526266731/d202685d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266731
- JSON: https://secwatch.observer/filing/0001193125-26-266731.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.